Skip to main content

Table 1 Population descriptive

From: Association of lysophosphatidic acids with cerebrospinal fluid biomarkers and progression to Alzheimer’s disease

 

ACE cohort

Heidelberg/Mannheim cohort

P value of difference

MCI patients (N)

142

40

 

Metabolomics profiling tissue

CSF and plasma

CSF

 

Age (SD) blood collection, years

71.94 (7.74)

68.85 (8.50)

0.042

Female (%)

74 (52%)

22 (55%)

0.747

Body mass index (SD)

26.46 (3.74)

25.85 (3.61)

0.353

Lipid-lowering medication user (%)

63 (44%)

11 (27%)

0.055

Amyloid-beta 42 in pg/mL (SD)

791.59 (337.36)

690.84 (397.13)

0.151

P-Tau in pg/mL (SD)

71.37 (37.30)

63.17 (29.96)

0.153

Total tau in pg/mL (SD)

478.82 (253.45)

380.95 (326.97)

0.124

MMSE

24.93 (4.07)

26.55 (2.51)

2.67 × 10−3

CDR

0.50 (0.06)

0.55 (0.15)

0.047

APOE genotype N (%)

APOE 44/34/24

50 (35%)

18 (45%)

 

APOE 33

81 (57%)

18 (45%)

 

APOE 22/23

11 (8%)

4 (10%)

 
  1. Abbreviations: MCI mild cognitive impairment, SD standard deviation, CSF cerebrospinal fluid, MMSE the Mini-Mental State Examination, CDR clinical dementia rating, APOE apolipoprotein E gene